There is strong evidence from multiple epidemological studies that lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are correlated, independent of age or comorbidities as diabetes or hypertension. Although a direct causal relationship is not established yet, four pathophysio logical mechanisms can explain the relationship. These include alteration in nitric oxide bioavailability, a1-adrenergic receptor hyperactivity, pelvic atherosclerosis and sex hormones. This association has different clinical implications on the management of both disorders. Men seeking care for one condition should always be screened for complaints of the other condition. Sexual function should be assessed and discussed with the patient when choosing the appropriate management strategy for LUTS, as well as when evaluating the patient's response to treatment. Multiple large clinical trials have shown an improvement in LUTS after phosphodiesterase-5 (PDE5)-inhibitor treatment. PDE5 inhibitors show promise as a future treatment for LUTS, either in conjunction with existing therapies or as a primary treatment. There may be a potential therapeutic role for testosterone in LUTS treatment in cases of testosterone deficiency that needs to be investigated. Much further investigation is required, but it is evident that the association between LUTS and ED is fundamental for future therapies and possible preventative strategies.
Introduction
In recent years, increasing attention has been given to the interaction and relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). Both complaints are highly prevalent in the aging male and share common risk factors, such as hypertension, hypercholesterolemia and diabetes mellitus. Aside from these common denominators, an independent association has been elucidated in a number of large-scale international trials. There is a strong correlation between age and ED, with prevalence increasing steadily from 6.5% in men aged 20-39 years to 77.5% in those 75 years and older. 1 A similar increase in the prevalence of LUTS in men has been observed from somewhat o1 in 10 in men aged 30-39 years to 41 in 3 in men aged 60-69 years. 2 In total, as much as three in four men are likely to experience LUTS sometime during their lifespan. 3 Both disorders have a major impact on quality of life (QoL) on individual patients, and further have a major socio-economic impact. In this review, we focus on the epidemiological and pathophysiological correlation of LUTS and ED, and discuss the impacts of this association on the clinical management of both disorders.
LUTS and ED: clinical and epidemiological correlations
A large number of clinical population-based and longitudinal studies have shown a strong correlation between ED and LUTS. In the Cologne Male Survey, a study including approximately 5000 German men aged 30-80 years, one in five subjects suffered from ED. 4 Interestingly, the prevalence of LUTS was 72% in men with ED versus 38% in those without ED. 4 Additional analyses employing multiple logical regression showed that the presence of LUTS was a risk factor for ED. Moreover, this relationship was independent of the presence of other risk factors, such as age, hypertension, diabetes and pelvic surgery. 5 The multinational survey of the aging male is a multinational survey conducted to investigate the relationship between LUTS and sexual problems in aging men. 6 In this study, 12 815 men aged 50-80 years in the United States and six European countries were included. 5 In this survey, Rosen et al. 6 indicated a link between ED and LUTS, with ED being more prevalent in patients with increasing LUTS complaints. To illustrate this relationship, only a quarter of men who had no LUTS suffered from ED, while four in five men with severe LUTS had reduced or no erections. Similarly, it was shown in the Cologne study that the relationship between LUTS and sexual dysfunction was independent of the effects of age, other comorbidities and lifestyle factors. These results were corroborated by McVary et al., 7 who reported a strong correlation between baseline American Urological Association (AUA) symptom index and the various domains of sexual function. The association between LUTS and ED was examined prospectively in 17 086 men in the health professionals follow-up study. The risk of ED increased with rising LUTS severity with stronger correlation in younger than in older men. 8 This correlation was proved worldwide as evidenced by the results of the Asian Survey of Aging Males study. This survey was carried out in Asian men aged 50-80 years from five Asian countries. The study results confirmed the correlation with sexual disorders increased with age and increasing severity of the LUTS. Erectile and ejaculation problems were more common in men with diabetes or hypertension. These two groups (diabetic and hypertensive patients) showed higher prevalence of ED and ejaculatory dysfunction. There was a significant increase in abnormal and painful ejaculation in men with hypertension. 9 LUTS is typically classified in obstructive (voiding) symptoms and irritative (storage) symptoms. While many of the above mentioned and other studies have reported correlations of LUTS and ED, only few reports have determined exactly what LUTS domain is related to which aspect of erectile, and more general, male sexual function. Standardized questionnaires like the international prostate symptom score (IPSS) for LUTS and the inter national index of erectile function (IIEF), and its abridged version (IIEF-5 or sexual health inventory for men (SHIM)) for sexual and erectile function have helped to clarify this relationship. If the symptom(s) that should be addressed to improve sexual function could be identified, more effective treatments for patients with comorbid LUTS and ED may lie ahead. A small number of studies have shown that severity of sexual dysfunction in the presence of LUTS was related more to the severity of the voiding symptoms and QoL. Also, the improvements in voiding symptoms, IPSS-QoL and uroflow were significantly related to enhanced sexual function. In the US Veterans Administration Survey, a total of 181 male veterans were asked to submit an SHIM and an IPPS questionnaire. An inverse correlation was observed between obstructive and not the irritative LUTS and SHIM score across age groups, indicating that those with worse obstructive symptoms also suffered from worse ED, with the strongest effect for men aged 60-70 years. Although a small positive correlation between the urinary flow rate and SHIM score and negative correlation between the post-void residual volume and the SHIM score were found, these results were not statistically significant. 10 In an Austrian study, in 2858 men aged 20-80 years, the presence of LUTS, in particular voiding symptoms, nocturia and the QoL impairment due to LUTS, was independent risk factors for the presence of ED.
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This may be due to psychosocial factors or pathophysiologic factor as the affection of penile vascularity by lower urinary obstruction. Khan et al.
12 created partial bladder outlet obstruction (BOO) by ligating the proximal urethra of adult male rabbits. After 3-6 weeks, the experimental rabbit corpora cavernosa showed increased collagen deposition with loss of smooth muscle and loss of staining for endothelin-1.
LUTS and ED: pathophysiological correlations
The association between LUTS and ED has been explained by four major common pathophysiologic mechanisms. These changes include alteration in nitric oxide (NO) bioavailablity, increased smooth muscle contractility, atherosclerosis and changes in circulating sex hormone levels. Risk factors for ED are also risk factors for LUTS, and signaling pathways and mechanisms of smooth muscle contr action in the penis are comparable with those mechanisms for smooth muscle contraction in the bladder neck, prostate and urethra. Understanding the common denominators of LUTS and ED may help us in diagnosis and, more importantly, treatment choice. Studies in both animal models and humans have contributed significantly to our understanding of the relationship between these two entities.
Altered NO levels NO has been identified as the capital signaling molecule for penile erection. The discovery of the NO signaling pathway in penile tissue has led to a Association of lower urinary tract symptoms and erectile dysfunction H Orabi et al revolution in ED research and to the development of phosphodiesterase-5 (PDE5) inhibitors, which now constitute first-line therapy for men with ED. 13 In recent years, it has been recognized that reduced NO availability is linked to the development of prostate gland hyperplasia and the subsequent development of LUTS. As a logical result, there is an increasing interest in the NO pathway as a potential pharmacological target to treat male LUTS. Nitric oxide synthase (NOS) is found in the normal prostate in two isoforms: endothelial NOS in the endothelial cells and under the form of neuronal NOS not only in nerve fibers transversing the fibromuscular prostatic stroma, but also, interestingly, in the cytoplasm of the basal cells. 14, 15 It has been reported that NOS expression, and thus NO production, of the prostate is reduced in the transition zone of the prostate in benign prostatic hyperplasia (BPH), compared with normal prostate tissue. 16 The proposed reduction in expression of NOS isoforms results in increased smooth muscle cell contractile forces at the bladder neck and prostatic urethra. Additionally, the resulting NO bioavailability results in prostatic smooth muscle cell proliferation, which further contributes to increased outlet resistance. Putative mechanisms responsible for this decrease in NOS bioavailability include accelerated breakdown of NO by reactive oxygen species, and alterations in the phosphorylation and expression of NOS isoforms. 17, 18 An in vitro model demonstrated an anti-proliferative effect on human prostatic smooth muscle cells by NO donors (sodium nitroprusside), increased cell proliferation with NO antagonists and a negative effect on the proliferation signal transduction pathway (protein kinase C) with sodium nitroprusside. 19 In vivo animal studies also suggest that NO has a role in preventing bladder contractions that result in bladder hyperactivity, the physiological correlate of irritative LUTS. Neuronal NOS knock-out mice were shown to have hypertrophied and dilated bladders and dysfunctional urinary tract outlets, which did not relax to electrical field stimulation or L-arginine, a precursor of NO. These mice displayed increased frequency of micturition. 20 In another study, blockade of the NO pathway influenced the function of the lower urinary tract, as studied by cystometry in conscious rats and in vitro, in isolated muscle strips from the rat detrusor and urethra. 21 The theory that NO has a role in the development of LUTS is further supported by the characterization and functional relevance of PDE isoenzymes in the human prostate, urethra and bladder wall. 22 Importantly, this also opens the avenue toward a potential benefit of PDE5-inhibitor therapy in LUTS. In rats, PDE5 expression is highest in the bladder, where it is expressed approximately 10-fold more than in the rat corpus cavernosum. 23 In an in vivo BOO model in which rat urethras were narrowed with a silk ligature was used, chronic treatment with 10 mg kg -1 per day of vardenafil significantly reduced bladder nonvoiding contractions by 47% compared with placebo. Tamsulosin demonstrated a comparable 51% reduction in nonvoiding contractions. The same study demonstrated inhibition of human prostate stromal cell proliferation with vardenafil in vivo. 23 Tinel et al. 24 utilized a rat model that demonstrated a PDE-inhibitor dosedependent reduction in smooth muscle contraction of bladder, urethral and prostate strips. A reduction in bladder nonvoiding contractions was noted in the rat BOO model after administration of sildenafil and vardenafil. The same study demonstrated inhibition of human prostate stromal cell proliferation with vardenafil in vivo. Interestingly, a recent discovery was made of PDE5 expression in the striated muscle of the urethra and levator ani in rats. 25 This finding was surprising, as it was previously believed that PDE5 was not expressed, or not of relevance, in striated muscle fibers. The discovery of PDE5 expression in striated muscle of the urethra and levator ani could lead to better understanding of urethral relaxation and pelvic floor disorders, both of which can manifest as LUTS. The exact role of PDE5 in these striated muscles needs to be further examined.
Increased smooth muscle contractility a1-Adrenergic receptors have an important role in mediating the tone of smooth muscle cells in various tissues. Various a1-adrenergic receptor subtypes have been identified in the lower urinary tract, including a1A and a1D receptors in prostatic stromal cells, 26, 27 a1B receptors in epithelial cells, a1A and a1B receptors in vascular smooth muscle, 28 a1A and a1D receptors in the urethra and bladder and a1D receptors in the detrusor muscle. 29 Penile erection and flaccidity depend on a balance between contraction and relaxation of the corpus cavernosum smooth muscle. 30 In various forms of ED, the balance favors smooth muscle contraction rather than relaxation. Noradrenaline is involved in the contraction of penile smooth muscle by activating a1-adrenergic receptors in the penile vasculature and corpus cavernosum smooth muscle, with androgens regulating the responsiveness of these receptors. 31 In certain human arteries, a1-receptor expression increases and the relative proportion of a1-adrenergic receptor subtypes is modulated by aging. 28 These changes might be happening as well in the human prostatic, bladder and erectile tissue. The contractile response of the smooth muscle strips to phenylephrine was greater for those strips isolated from the corpus cavernosum of older (460 years) men with ED than for those isolated from younger (o60 years) men with ED. This marked difference suggests that aging has a role in adrenergic sensitivity in patients with ED. 32 Furthermore,
Association of lower urinary tract symptoms and erectile dysfunction H Orabi et al elevated serum epinephrine levels were found in men with ED and there was a negative association between serum levels of epinephrine on the one hand, and IEFF-5 and IPSS on the other hand. It was concluded that the potential for an increase in sympathetic tone may be one of the common denominators of the two disease processes. 33 It has been suggested that a1-adrenergic receptors are upregulated in patients with LUTS associated with BPH, resulting in increased smooth muscle tone in the prostatic capsule and bladder neck. 34 Rat models have demonstrated an effect on prostatic growth and differentiation through manipulation of autonomic activity. 35 Not only can changes at the level of adrenergic receptor expression and circulating sympathetic neurotransmitters explain a link between ED and LUTS, but also changes at the level of the myosinactin filament interaction leading to smooth muscle hypercontractility have further been described in both diseases. Contraction of smooth muscle is stimulated by the inhibition of myosin light chain phosphatase by Rho kinase, and, therefore, provides a calcium-independent mechanism for smooth muscle contraction. Thus, an abnormally upregulated Rho-kinase pathway could contribute to a lack of smooth muscle relaxation, changes in bladder compliance and thus LUTS. Upregulation of Rho kinase has indeed been linked to both ED and LUTS in various studies. 36, 37 Furthermore, the relaxant and anti-proliferative effect of Rho-kinase inhibitors corroborated this finding. 38 The suggestion that BOO induces ED via an upregulation of Rho kinase in the penis has experimental merit. 39 There is also a possibility that a multisystem dysfunction of Rho kinase exists and leads to both ED and LUTS. 40 Rho kinase has further been shown to have a role in hypertension and its expression correlates to aging, which provides a partial explanation not only for the relationship between LUTS and ED, but also for the connection of LUTS, ED and hypertension. 41 Pelvic atherosclerosis An additional mechanism is diffuse atherosclerosis of blood vessels supplying prostate, penis and bladder. 42 In a recent epidemiologic study that supports this notion, both men and women who had two risk factors of atherosclerosis (diabetes mellitus, hypertension, hyperlipidemia and nicotine use) had a statistically significant higher IPSS compared with subjects with one or no risk factors. 43 Another epidemiologic study showed that men with risk factors for vascular disease are more likely to have a higher IPSS and a lower IIEF score than men without risk factors. 44 In a prospective office-based study, a total of 374 male patients with ED were enrolled to assess if there is an underlying vascular association between LUTS and ED. The study concluded that reduced peak systolic velocity of the cavernous arteries correlates with LUTS in patients with ED. 45 Animal models mimicking pelvic ischemia and hypercholesterolemia show a striking similarity in the smooth muscle alterations of the detrusor muscle and corpora cavernosa. In the rabbit, chronic ischemia resulted in fibrosis, smooth muscle atrophy and decreased compliance of the bladder. 46 Similar studies involving the prostate showed that chronic ischemia resulted in stromal fibrosis, glandular cystic atrophy and increase in smooth muscle contractility of the rabbit prostate, 47, 48 and persistent hypoxia caused penile fibrosis in the corpus cavernosum tissue. There are several potential mechanisms to explain these findings. Chronic ischemia is associated with an increased production of profibrotic and proapoptotic cytokines, such as transforming growth factor-b1, which correlates with the severity of fibrosis. 46 Transforming growth factor-b1 further impairs neurogenic relaxation in the prostate, which appears to involve the NO pathway (see above), and may result in a loss of elasticity and an increase in smooth muscle tone of the prostate. 47 In fact, atherosclerosisinduced pelvic ischemia is likely compatible with all theories mentioned previously, as it may induce autonomic nervous system hyperactivity, reduce NOS expression and upregulate Rho kinase. 49 
Sex hormones
Androgens have been suggested to have an important role in the maintenance of the functional and structural integrity of the urinary tract. It is possible that declining testosterone production with aging contributes to the development of LUTS. 50 Androgen receptors have been found to be expressed in the epithelial cells of the urethra and the bladder of rabbits and in the urothelium, bladder smooth muscle, striated muscle cells of the proximal urethra and in the neurons in the autonomic ganglia of the prostatic plexus of the male rat. 51, 52 The role of testosterone and its metabolites on maintaining the reflex activity in the pelvic part of the autonomic nervous system has been demonstrated in rats. 53 Upon castration, electrically evoked relaxations of the smooth muscle of the prostatic urethra were decreased and this effect was ascribed to an impaired ability of the smooth muscle to respond to relaxant agents. 54 The effects of testosterone can be partially explained by the fact that NO production is androgen dependent in the urinary tract. NOS in an earlier study had appeared to be androgen dependent in the urogenital tract of the rat. 55 This is also true in the erectile apparatus. Longitudinal data from the Massachusetts Male Aging Study (MMAS) indicated that serum levels of total testosterone, dehydroepiandrosterone and dehydroepiandrosterone sulfate declined, whereas levels of dihydrotestosterone and sex hormone binding globulin, luteinizing hormone and foliclestimulating hormone increased with advancing Association of lower urinary tract symptoms and erectile dysfunction H Orabi et al age. 56 A recent study found that low testosterone levels in clinical BOO correlated negatively with detrusor pressure. 57 
Psychological factors
In addition to these four major pathophysiological associations, psychosocial factors have also been suggested. Frankel et al. 58 reported that urinary incontinence or painful urination could decrease social and sexual confidence and thus lead to ED. Elliott et al. 10 suggested that depression could reduce sexual function. In addition, changes in lifestyle due to nocturia and disorders of rapid eye movement sleep phase could lead to ED. 12 Whether having an either LUTS-or ED-related decreased mood impacts the development of the other disorder remains to be clarified.
LUTS and ED: effects on clinical management
At present day, oral agents, including a-adrenergic blockers either with or without associated anticholinergics are now the standard first-line therapy for men with bothersome and moderate-to-severe LUTS.
59 5a-Reductase inhibitors are an appropriate treatment option for patients with LUTS and evidence of marked prostatic enlargement. If pharmacological management fails, the classical open, or more often transurethral resection of the prostate (TURP) is the recommended treatment.
Impact of surgery for BPH on erectile function ED following surgical treatments for LUTS and/or prostatic diseases is not uncommon. A summary for the sexual side effects of the different therapies for BPH/LUTS is provided in Table 1 .
The estimated incidence of ED following TURP was 10% in 15 trials (versus 2% for control). 59 In contrast with these findings, the Veterans Affairs Cooperative Group study on TURP demonstrated that the incidence of ED in men with moderate LUTS/BPH who underwent TURP was actually lower than the incidence in the watchful waiting group. 60 Novel minimally invasive therapies, including transurethral microwave therapy and transurethral needle ablation induce sexual dysfunction to a lesser extent than TURP, with a rate of ED of approximately 3% (versus 3% for therapy and 10% for TURP). 59 Data from a number of small studies suggested that minimally invasive therapies may be associated with less sexual dysfunction when compared with TURP. [61] [62] [63] In a randomized comparison of TURP with holmium laser enucleating of the prostate, holmium laser enucleating of the prostate was not associated with worsening erectile function after surgery and there was no difference compared with TURP. 64 A number of studies related to Greenlight laser vaporization of the prostate describe no influence [65] [66] [67] or even improvement 68 of erectile function. In contrary to the previously mentioned studies, in another study in a group of preoperatively potent patients (IIEF-5418), a significant negative impact on erectile function following the Greenlight procedure was observed. 69 The reason for this discrepancy between studies remains unclear. One possible explanation might be use of definitions of potency between these studies. 70 Open surgery is associated with a high incidence of sexual dysfunction, reaching 10% for ED and 65% for ejaculatory dysfunction. 71 However, another study examining 60 men undergoing open prostatectomy for BPH did not note any change in sexual function scores as a result of surgery, suggesting that either prostat ectomy does not affect sexual function or that any deterioration as a result of the procedure was offset by a reduction in sexual dysfunction related to the observed improvement in LUTS. 72 The latter argument is putatively applicable to all (surgical and Association of lower urinary tract symptoms and erectile dysfunction H Orabi et al medical) therapies for LUTS, as it is complicated to distinguish between erectile function changes due to therapy versus due to relieve of LUTS complaints.
Impact of pharmacological treatment of LUTS on ED Pharmacological treatments of BPH are classically associated with a relatively lower risk of consequential sexual dysfunction compared with surgical intervention. 73 There has been some speculation that a-blocker therapy may result in improvements in sexual function as a result of improvements in LUTS. Again, as was explained above, it is difficult to determine whether this treatment improves LUTS and subsequently ED, or whether the treatment targets both processes by targeting a shared pathophysiology. In a Korean study, the correlation between LUTS and sexual function was investigated in 365 men with BPH. 74 After 3 months of treatment with a-blockers (n ¼ 304), they were assessed again to evaluate the effectiveness of the treatment. Various parameters of LUTS correlated significantly with the total and each domain of IIEF-5. Furthermore, changed urine flow rates correlated significantly with the improvement in total IIEF-5 and the EF domain. One open-label study assessed the effect of alfuzosin on sexual function in 3076 men over a 1-year period. 75 At the end point, alfuzosin significantly improved the total IPSS and urinary bother score versus baseline, and in those men with sexual dysfunction, there were significant improvements in rigidity of erection, amount of ejaculate and pain/discomfort on ejaculation versus baseline. These improvements were of a greater magnitude in men with severe LUTS or bother at baseline. In another study examining a-blocker use and sexual dysfunction among men participating in a population-based cohort, it was concluded that the use of a-blockers for LUTS was associated with a decreased risk of sexual dysfunction. Improvement in sexual function correlated with the improvement in LUTS more strongly among those using a-blockers. 76 In clinical trials involving sildodosin, the adverse effects were only ejaculatory disturbances and only 2.8% of patients discontinued treatment due to this adverse effect. 77 Placebocontrolled studies of 5a-reductase inhibitors have shown that ED occurs in 7-8% of men (placebo, 4-5%), decreased libido in 4-6% (placebo, 2-3%) and abnormal ejaculation in 1-2% (placebo, o1%). These events are more prominent in the first months of therapy, and the incidence tends to diminish with time. [78] [79] [80] [81] The Alfuzosin-Finasteride (ALFIN) study demonstrated that alfuzosin had little or no impact on sexual function, whereas finasteride and combination therapy (alfuzosin and finasteride) caused impairment of erectile and ejaculatory function. 82, 83 These findings have also been replicated in the larger scale, placebo-controlled Medical Therapy of Prostatic Symptoms study. 79 Impact of pharmacological treatment of ED on LUTS: PDE5 inhibitors Four possible pathophysiologic mechanisms have been described that may explain a potential role of PDE5-inhibitor therapy in LUTS. PDE5 inhibitors facilitate smooth muscle relaxation by inhibiting the breakdown of cyclic guanosine monophosphate, which is known as the second messenger of NO. Cyclic guanosine monophosphate subsequently phophorylates several other targets, leading to depletion of intracellular calcium. This leads to a dissociation of calmodulin from myosin light chain kinase and its inactivation (phosphorylation). Myosin is subsequently dephosphorylated by myosin light chain phosphatase, detaching from actin. This cascade ultimately results in smooth muscle relaxation. Effects and expression of PDE5 have been shown in the bladder, prostate and urethra. Beside that, PDE5 inhibitors have been shown to counter autonomic hyperactivity (which is mediated through increased norepinephrine and endothelin levels). Rho-kinase's effects are mediated in part by these same second messengers, and it can be affected also by PDE5 inhibitors. Pelvic atherosclerosis and ischemia have their effects via these concepts. 84 Several randomized, placebo-controlled studies to assess the effect of PDE inhibitors on LUTS using sildenafil, vardenafil and tadalafil were conducted. The study employing sildenafil used a 12-week, double-blinded, placebo-controlled approach in 369 men over 45 years of age who had IIEF scores under 26 (on erectile function domain) and IPSS scores 411. 85 The 189 men receiving sildenafil had significant improvement in IPSS and IIEF scores. BPH index, IPSS QoL score, total self-esteem and relationship questionnaire scores and overall treatment satisfaction were all significantly improved in the treatment arm. However, no difference in urinary flow rates was noted between the treatment and placebo arms.
The vardenafil study included 222 men aged 45-64 years who had an IPSS411 at the time of randomization between 8 weeks treatment of 10 mg twice daily versus placebo. 86 No history of ED was required for inclusion in the study. Vardenafil treatment resulted in a decrease in IPSS of 2.3 greater than placebo. Significant improvement was noted in QoL, irritative and obstructive IPSS subscores and IIEF scores in the treatment group. As in the sildenafil trial, no statistically significant improvement in Qmax was found in comparison with placebo. Post-voiding residual urine volume did not significantly change in the treatment group.
In the tadalafil study, following a 4-week, singleblind, placebo run-in, 281 men were randomly assigned to 5 mg tadalafil daily for 6 weeks, followed by dose escalation to 20 mg for 6 or 12 weeks of placebo. 87 Tadalafil significantly improved IPSS, although no differences were seen in uroflow 88 performed a dose-finding study using tadalafil for LUTS in 1058 men. The patients were assigned to placebo or one of four different tadalafil dosing regimens (2.5, 5, 10 or 20 mg daily). Significant improvement of LUTS was observed in the 5-mg group. Urinary flow rates did not show any change at any dosage level in comparison with placebo. Increasing the tadalafil dosage 45 mg (10 or 20 mg) resulted in similar improvements in IPSS, but at the cost of a higher incidence of adverse effects. The sexually active men (55%) showed a significant improvement in IIEF scores. Tadalafil has its therapeutic effects through beneficial actions on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity and tissue perfusion. 89 Significant improvement in IPSS after PDE5-inhibitor therapy compared with placebo was reported in all clinical studies with the magnitude of IPSS improvement comparable with those reported in previous a-blocker studies. Interestingly, none of the studies showed a significant effect of PDE5-I on peak urinary flow rate. This may be explained by the hypothesis that PDE5 inhibitors primarily affect detrusor activity rather than the BOO. 90 A study by Gacci et al. 91 in men with neurogenic bladders secondary to spinal cord injury showed that vardenafil treatment resulted in significant improvements in maximum detrussor pressure, total capacity and volume triggered bladder spasms.
A recent study by Dmochowski et al. 92 examined LUTS and urodynamic parameters in 200 men (baseline IPSS ¼ 13) randomized to tadalafil (20 mg) treatment or placebo for 12 weeks. Although no difference was noted in urodynamic parameters after treatment (including BOO index), IPSS improved significantly in the treatment group compared with placebo. Additionally, the proportion of obstructed patients in the treatment group decreased, whereas the proportion in the placebo group increased.
A new PDE-5 inhibitor, udenafil, is approved for use in South Korea and the United Kingdom and currently under further investigation in the United States. 93 A trial combining udenafil and an a-blocker in men with ED concomitant with BPH and LUTS showed that the co-administration of udenafil and an a-blocker in patients with both BPH and ED was safe, and patients showed significant improvements in both LUTS and ED. 94 Two more studies investigating the combination of a-blocker and PDE-5 inhibitor to treat LUTS and ED concluded that the combination of the two drugs is safe and more effective than monotherapy with either agent to improve both voiding and sexual dysfunction in men with LUTS suggestive of BPH. 95, 96 Effects of testosterone used for treatment of hypogonadism on LUTS A number of studies involving the use of testo sterone for ED or late onset hypogonadism, investigated the effects of testosterone administration to elderly men on symptoms of LUTS. Saad et al. 97 described the effects of administration of parenteral testosterone undecanaote over 12 months. There were positive clinical effects of administration of testosterone suppletion on the IPSS as well as on parameters of the metabolic syndrome, progressing over the 12-month study period. Since the effects were progressive over the 12 months of the study, it is likely that the effects take time to occur following testosterone administration. The same authors concluded in a separate study that there were positive clinical effects of administration of testosterone gel on the IPSS and also on parameters of the metabolic syndrome, and there was a significant further improvement of the IPSS when testosterone undecanaote was administered after 9 months of administration of testosterone gel when plasma testosterone levels increased to higher levels than with testosterone gel. 98 This can be explained by the decreased levels of free and total testosterone associated with the presence of metabolic syndrome, as well as with many of its components: obesity, dyslipidemia and insulin resistance. Metabolic syndrome can contribute to testosterone deficiency through decreased sex hormone binding globulin levels; suppression of gonadotrophin release or Leydig cell testosterone production; and cytokine-mediated inhibition of testicular steroid production. 99 Testosterone deficiency may be a pathophysiological mechanism connecting LUTS and ED with the metabolic syndrome in men. Decreased testosterone can cause LUTS through relaxations of the smooth muscle of the prostatic urethra and bladder (see above). Regarding ED, in addition to downregulation of many pro-erectile molecular mechanisms as (cyclic guanosine monophosphate) formation, decreased testosterone levels upregulate corpus cavernosum smooth muscle contractile signaling and downregulates corpus cavernosum smooth muscle relaxation pathways synergizing to produce ED. 100 Haide et al. 101 investigated the effects of normalization of testosterone levels in hypogondal elderly men on LUTS. Along with the improvement of the metabolic syndrome upon testosterone administration, there was also an improvement of the IPSS and residual bladder volume of urine. The delayed and progressive effect of testosterone on LUTS is intriguing. More studies at molecular level are needed to elucidate the mechanism as well as planning larger clinical trials.
Association of lower urinary tract symptoms and erectile dysfunction H Orabi et al
Conclusions
LUTS and ED are common disorders in aging men, which are independently associated to one another. The two disorders share certain pathophysiologic mechanisms and this association has many clinical implications. It is recommended that men presenting with LUTS should be evaluated for sexual dysfunction and ED in particular, and those presenting with sexual dysfunction should be evaluated for LUTS. Patients should further be screened for risk factors for underlying disorders. In treating LUTS, the presence or absence of sexual dysfunction may affect the choice of therapy, especially once patient preferences are considered. For this indication, the introduction of PDE-5 inhibitors is gaining acceptance. In patients with obstructive LUTS, the association of an a-blocker may be of benefit. Ongoing research is further elucidating these complex interactions, and might hold promise for future therapy of men suffering from both LUTS and ED.
